Compare ProShares UltraShort Bloomberg Natural Gas ETF (KOLD) vs Organon & Co. Common Stock (OGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ProShares UltraShort Bloomberg Natural Gas ETF vs Organon & Co. Common Stock — how do they compare? ProShares UltraShort Bloomberg Natural Gas ETF trades at $24.05 (market cap $140.85M), while Organon & Co. Common Stock trades at $13.58 (market cap $3.62B). The key difference: Organon & Co. Common Stock is far larger — about 25.7× ProShares UltraShort Bloomberg Natural Gas ETF's market cap, and Organon & Co. Common Stock pays a 0.58% dividend while ProShares UltraShort Bloomberg Natural Gas ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold ProShares UltraShort Bloomberg Natural Gas ETF for 10 Days and Organon & Co. Common Stock for 0 Days on average.
| KOLD | OGN | |
|---|---|---|
Market Cap | $140.85M | $3.62B |
Volume | 4,297,516 | 2,892,999 |
Sector | Leveraged / Inverse | Health |
52-Week High | $49.39 | $13.81 |
52-Week Low | $13.58 | $5.70 |
Typical Hold Time | 10 Days | 0 Days |
Enterprise Value | — | $11.04B |
Dividend Yield | — | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
KOLD is trading at $23.85, down 5.06% over the past 24 hours amid bearish technical signals. The stock shows significant selling pressure with 16 sell signals versus 1 buy signal across technical indicators. Natural gas market fundamentals remain challenging with record-high U.S. production reported by the EIA in July 2026, while geopolitical tensions in the Middle East create volatility in energy markets.
The outlook remains cautious as technical indicators point to continued downward momentum. Investment opportunities exist for contrarian investors given the oversold RSI reading, but risks include persistent natural gas price weakness and high production levels that may pressure energy sector performance in the near term.
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About ProShares UltraShort Bloomberg Natural Gas ETF
KOLD is an inverse leveraged ETF that seeks to provide two times (2x) the inverse daily performance of the Bloomberg Natural Gas Subindex. It is designed for investors looking to profit from falling natural gas prices.
Read more on KOLD →About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →
